HCPCS Level II code J1322 designates a 1 mg unit of elosulfase alfa, an enzyme replacement therapy administered by injection or infusion. This code matters nationally because specialty biologic therapies carry high per-dose costs, have specific billing and coding requirements, and influence payer coverage policies and utilization management for rare metabolic disorders. The analysis covers major national payers and Medicare.

Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for elosulfase alfa, typical sites of service where the drug is delivered, and what the code captures on the claim line. The publication outlines benchmarks and reimbursement considerations that affect billing for high-cost injectable biologics, common modifier usage patterns where available, and the operational implications for provider billing workflows.

This summary provides actionable reference material for revenue cycle, coding compliance, and payer engagement teams seeking a national perspective on billing and reporting for J1322. Data not available in the input is noted where applicable rather than inferred.